SOLICITATION NOTICE
B -- Testing the efficacy of candidate Alzheimer's disease treatments in rescuing impaired hippocampal synaptic plasticity
- Notice Date
- 8/3/2023 1:58:08 PM
- Notice Type
- Solicitation
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NIDA Bethesda MD 20892 USA
- ZIP Code
- 20892
- Solicitation Number
- 75N95023Q00439
- Response Due
- 8/8/2023 2:00:00 PM
- Archive Date
- 08/23/2023
- Point of Contact
- Fred Ettehadieh
- E-Mail Address
-
Fred.Ettehadieh@nih.gov
(Fred.Ettehadieh@nih.gov)
- Description
- �(i)������� This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii)������� The solicitation number is 75N95023Q00439 and the solicitation is issued as a request for quotation (RFQ). ����������� This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13�Simplified Acquisition Procedures; �and FAR Part 12�Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold. THIS IS A NON?COMPETITIVE COMBINED (NOTICE OF INTENT) SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND?NAME).�� The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA), on behalf of the National Institute on Aging (NIA), intends to negotiate and award a purchase order without providing for full and open competition (including brand-name) to NATIONAL UNIVERSITY OF SINGAPORE, 21 LOWER KENT RIDGE ROAD, UNIVERSITY HALL, LEE KONG CHIAN WING, UHL-05-02, SINGAPORE. This acquisition is conducted as non-competitive for a commercial service and is conducted pursuant to FAR 13.106-1(b)(1). The rationale for the brand-name justification: The electrophysiological studies in the proposed acquisition will characterize the ability of candidate AD drugs to rescue a form of hippocampal synaptic plasticity called late long-term potentiation (L-LTP) which is believed to be important for the brain to store and retrieve remote memories. Impaired L-LTP is thought to be responsible for cognitive impairment in AD as well as age-associated cognitive impairment. This fundamental biological phenomenon is dependent on the synthesis of synaptic proteins through a mechanism called synaptic tagging and capture (STC). Characterization of L-LTP and STC in hippocampal slice preparations from transgenic AD mouse models requires sophisticated equipment and highly skilled personnel to generate these data. Their interpretation must be performed by an experienced scientist with highly specialized expertise in synaptic physiology. It is critical that the study in the proposed acquisition is performed in the same laboratory and with the same methods and protocols used in prior studies currently being performed under contract 75N95021P00404. (iii)������ The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) Number 2023-04, with effective date June 2, 2023. (iv)������ The associated NAICS code 621511 and the small business size standard $41.5 million. This requirement has no set-aside restrictions. (v)������� This requirement is for the following services: There is currently a pressing need to identify effective treatments for Alzheimer�s disease (AD). With the repeated failures of multiple pivotal phase-III clinical trials in patients with AD, it is critical to test novel methods of discovering disease-modifying AD treatments. As part of a recently completed study called the Drug Repurposing for Effective Alzheimer�s Medicines (DREAM) study, the National Institute on Aging (NIA) Intramural Research Program (IRP) is testing whether exposure to commonly prescribed, Food and and Drug Administraton (FDA)-approved drugs will be associated with protection against AD. DREAM has tested approximately 20 drugs that NIA have nominated as �candidate AD treatments.� NIA has selected the most promising drugs from the DREAM study to test in the recently funded Experimental Validation of candidate Alzheimer�s disease treatments identified by multi-omics analyses (PREVENT-AD) study. The NIA is additionally testing additional FDA approved and experimental drugs in ongoing contracts including phenotypic screening in cell culture. In the proposed acquisition, NIA will test the efficacy of the most promising drugs (emerging from the DREAM study, the PREVENT-AD study, ongoing contracts and proteomic/ metabolomic studies in the NIA IRP) to determine whether they rescue impaired hippocampal synaptic plasticity. This will be accomplished by studying their effects on late long term potentiation (LTP) in hippocampal slices obtained from the APP/PS1 transgenic AD mouse model. (vi)������ Project requirements: Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, material, equipment, and facilities, not otherwise provided by the Government as needed to perform the Statement of Work attached to this notice. (vii)����� Anticipated periods of performance: September 30, 2023 � September 29, 2025 The Government anticipates award of a firm fixed-price purchase order. (viii)���� The provision at FAR 52.252-1, Solicitation Provisions Incorporated by Reference (Feb 1998), applies to this acquisition. This solicitation incorporates one or more solicitation provisions by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. The offeror is cautioned that the listed provisions may include blocks that must be completed by the offeror and submitted with its quotation or offer. In lieu of submitting the full text of those provisions, the offeror may identify the provision by paragraph identifier and provide the appropriate information with its quotation or offer. Also, the full text of a solicitation provision may be accessed electronically at these addresses:� https://www.acquisition.gov/browse/index/far ��https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html �� ����������������������������������������������������������� (End of provision) The following provisions apply to this acquisition and are incorporated by reference: FAR 52.204-7, System for Award Management (Oct 2018) FAR 52.204-16, Commercial and Government Entity Code Reporting (Aug 2020) FAR 52.211-6, Brand Name or Equal (AUG 1999) FAR 52.212-1, Instructions to Offerors-Commercial Items (Nov 2021) FAR 52.212-3, Offeror Representations and Certifications-Commercial Items (Nov 2021) FAR 52.225-4, Buy American-Free Trade Agreements-Israel Trade Act Certificate ��(May 2014) HHSAR 352.239-73, Electronic and Information Technology Accessibility Notice (December 18, 2015) The clause at FAR 52.252-2, Clauses Incorporated by Reference (Feb 1998), applies to this acquisition. This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at these addresses: https://www.acquisition.gov/browse/index/far ����https://www.hhs.gov/grants/contracts/contract-policies-regulations/hhsar/index.html � (End of clause) The following clauses apply to this acquisition and are incorporated by reference: FAR 52.204-13, System for Award Management Maintenance (Oct 2018) FAR 52.204-18, Commercial and Government Entity Code Maintenance (Aug 2020) FAR 52.212-4, Contract Terms and Conditions-Commercial Items (Nov 2021). Addendum to this FAR clause applies to this acquisition and is attached. HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (December 18, 2015) HHSAR 352.239-74, Electronic and Information Technology Accessibility (December 18, 2015) The following provisions and clauses apply to this acquisition and are attached in full text.� Offerors MUST complete the provisions at 52.204-24 and 52.204-26 and submit completed copies as separate documents with their proposal. FAR 52.204-24 Representation Regarding Certain Telecommunications and Video Surveillance Services or Equipment (Nov 2021) FAR 52.204-26 Covered Telecommunications Equipment or Services-Representation (Oct 2020) FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Items (May 2022) Invoice Instructions Without IPP (ix)������ The provision at FAR clause 52.212-2, Evaluation-Commercial Items (Nov 2021), applies to this acquisition.� (a) The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate offers: (i) technical capability of the item offered to meet the Government requirement; (ii) past performance [see FAR 13.106-2(b)(3)]; (iii) price. Technical capability and past performance, when combined, are significantly more important than price. (b) A written notice of award or acceptance of an offer, mailed or otherwise furnished to the successful offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer�s specified expiration time, the Government may accept an offer (or part of an offer), whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award. If you are providing an �equal� product, you must submit additional documentation that highlights and describes how your offering is equal in accordance with FAR clause 52.211-6. (x)������� The Offerors to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications-Commercial Items (Nov 2021), with its offer. If the offeror has completed FAR clause 52.212-3 at www.sam.gov, then the offeror does not need to provide a completed copy with its offer. (xi)������ The clause at FAR 52.212-4, Contract Terms and Conditions-Commercial Items (DEC 2022), applies to this acquisition. Addendum to this FAR clause applies to this acquisition and is attached. (xii)����� There are no additional contract requirement(s) or terms and conditions applicable to this acquisition. (xiii)���� The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (xiv)���� Responses to this solicitation must include sufficient information to establish the interested parties� bona-fide capabilities of providing the product or service. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s), product description, and any other information or factors that may be considered in the award decision. Such factors may include: past performance, special features required for effective program performance, trade-in considerations, probable life of the item selected as compared with that of a comparable item, warranty considerations, maintenance availability, and environmental and energy efficiency considerations. Respondents proposing on an equal product of the brand-name product specified in this announcement must provide, as part of their response: (a) product, catalog, model, and/or part number(s); (b) product description; (c) all relevant information and documentation that the item(s) offered meets the salient physical, functional, or performance characteristics as specified in the purchase description; quantity; estimated price or cost; shipping, handling, and/or installation charges; and delivery date after receipt of order. The Unique Entity ID from SAM.gov, the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. All quotations must be submitted electronically (by email) to Fred Ettehadieh,�Contracting Officer, at Fred.Ettehadieh@nih.gov by the closing date and time of this�solicitation, and reference Soliciataion number 75N95023Q00439.� Fax responses will not be accepted.
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/cc490c9a4a454b6d952d33ecfd47104d/view)
- Place of Performance
- Address: MD, USA
- Country: USA
- Country: USA
- Record
- SN06775056-F 20230805/230803230048 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |